Name:
In Focus: cellular starting materials for cell therapies
Description:
In Focus: cellular starting materials for cell therapies
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/812ef6eb-6c59-4396-bb9a-3f59970d9d2f/videoscrubberimages/Scrubber_2.jpg
Duration:
T00H01M23S
Embed URL:
https://stream.cadmore.media/player/812ef6eb-6c59-4396-bb9a-3f59970d9d2f
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/812ef6eb-6c59-4396-bb9a-3f59970d9d2f/RMN In Focus CSM V2.mp4?sv=2019-02-02&sr=c&sig=QfymHyCC%2B7nQqULxgfzzP4qyUBPlucPBRaUw9RxDtcI%3D&st=2024-05-01T14%3A58%3A09Z&se=2024-05-01T17%3A03%3A09Z&sp=r
Upload Date:
2021-04-06T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
SPEAKER: Hello, and welcome to ReMedNet. This month, we're putting cellular starting materials in focus. Cellular starting materials are a crucial aspect in the development of cell therapies. However, starting materials that involve a cell preparation can be a significant source of variability when it comes to the final product, especially when considering donor-specific cells. Because of this, it's essential to ensure that the starting materials used for these therapies are carefully evaluated in order to minimize this variability and to help improve the likelihood of clinical translation.
SPEAKER: In this feature, we will explore the advantages that various cellular starting materials have with a particular focus on human-induced pluripotent stem cells. In contrast to harvesting and altering differentiated cells from patients, which is known as an autologous approach, using induced pluripotent stem cells as starting materials for cell therapies can expand the diversity of therapeutic cell types, extend the longevity of the starting material source, and reduce logistical hurdles.
SPEAKER: We will also be speaking to experts from brain cell therapeutics to discuss the challenges behind establishing induced pluripotent stem cells as starting materials. In addition to this, we'll explore what starting material features can help transform cell therapies into standard care. Join the conversation today at regmednet.com or follow the discussion on Twitter, Facebook, and LinkedIn. I'll see you there.